MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model

被引：19
|
作者：
Turetschek, K [1 ]
Preda, A
Floyd, E
Shames, DM
Novikov, V
Roberts, TPL
Wood, JM
Fu, YJ
Carter, WO
Brasch, RC
机构：
[1] Univ Calif San Francisco, Dept Radiol, Ctr Pharmaceut & Mol Imaging, San Francisco, CA USA
[2] Univ Vienna, Dept Radiol, A-1090 Vienna, Austria
[3] Pfizer Cent rs, Groton, CT USA
[4] Novartis Pharma AG Ltd, Dept Oncol Res, Basel, Switzerland
来源：
ACADEMIC RADIOLOGY | 2002年 / 9卷
关键词：
D O I：
10.1016/S1076-6332(03)80281-7
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S519 / S520
页数：2
相关论文
共 50 条
  • [1] MRI monitoring of tumor response following anglogenesis inhibition in an experimental human breast cancer model
    Turetschek, K
    Preda, A
    Floyd, E
    Shames, DM
    Novikov, V
    Roberts, TPL
    Wood, JM
    Fu, YJ
    Carter, WO
    Brasch, RC
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (03) : 448 - 455
  • [2] MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model
    Karl Turetschek
    Anda Preda
    Eugenia Floyd
    David M. Shames
    Viktor Novikov
    Timothy P. Roberts
    Jeanette M. Wood
    Yanjun Fu
    Wayne O. Carter
    Robert C. Brasch
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 448 - 455
  • [3] CTEN and LKB1: novel tumor biomarkers for breast cancer implications of resistance and response to tyrosine kinase inhibitor (TKI)-based therapies in breast cancer
    Yarden, Y.
    Shell, S. A.
    Spector, N. L.
    Bacus, S. S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S159 - S159
  • [4] Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy
    Sloan, Barry
    Scheinfeld, Noah S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (12) : 1324 - 1335
  • [5] Pharmacodynamics of tumor response to tyrosine kinase inhibitors of VEGF receptors
    Kim, D
    Geng, L
    Niermann, K
    Lee, H
    Hallahan, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S148 - S149
  • [6] MRI Methods for Evaluating the Effects of Tyrosine Kinase Inhibitor Administration Used to Enhance Chemotherapy Efficiency in a Breast Tumor Xenograft Model
    Aliu, S. O.
    Wilmes, L. J.
    Moasser, M. M.
    Hann, B. C.
    Li, K. -L.
    Wang, D.
    Hylton, N. M.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2009, 29 (05) : 1071 - 1079
  • [7] DYNAMIC MRI FOR TUMOR ENHANCEMENT: AN EXPERIMENTAL BREAST CANCER MODEL
    Leung, Ting-Kai
    Huang, Pai-Jung
    Lee, Chi-Ming
    Wu, Chih-Hsiung
    Chen, Yi-Fan
    Shen, Li-Kuo
    Hsiao, Wen-Tien
    BIOMEDICAL ENGINEERING-APPLICATIONS BASIS COMMUNICATIONS, 2013, 25 (01):
  • [8] TKI258, a novel, multitargeted tyrosine kinase inhibitor for the treatment of breast cancer
    Liu, H.
    Schulz, C. O.
    Regierer, A. C.
    Dieing, A.
    Possinger, K.
    Eucker, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Oncolytic Potential of a Novel KGFR Tyrosine Kinase Inhibitor Using a KGFR-selective Breast Cancer Xenograft Model
    Kesinger, Jason W.
    Mehta, Meghna
    Lerner, Megan R.
    Brackett, Daniel J.
    Brueggemeier, Robert W.
    Li, Pui-Kui
    Pento, J. Thomas
    ANTICANCER RESEARCH, 2015, 35 (01) : 47 - 52
  • [10] Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
    Mukherjee, A.
    Dhadda, A. S.
    Shehata, M.
    Chan, Stephen
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) : 2189 - 2204
12345